Physician profile
Zhen Wang
NPI 1619396967
$3,929.62
in general payments reported to CMS, 2019-2025
52 companies · $1,537 in 2025
The $1,537 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.06 · 2021: $301 · 2022: $1,175 · 2023: $474 · 2024: $374 · 2025: $1,537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,048 · Education: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,047.61 |
| Education | $337.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $421.87 | 2021-2025 | Imfinzi, Lynparza, Calquence |
| Novartis Pharmaceuticals Corporation | $354.70 | 2021-2025 | |
| Astellas Pharma US INC | $196.87 | 2022-2024 | |
| Abbvie INC. | $192.95 | 2022-2025 | Venclexta |
| Pfizer INC. | $191.99 | 2021-2025 | |
| Daiichi Sankyo INC. | $189.18 | 2022-2025 | Injectafer, Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $171.29 | 2022-2025 | Keytruda, Reblozyl, Lynparza |
| Janssen Biotech, INC. | $145.36 | 2021-2025 | Darzalex |
| Genzyme Corporation | $144.63 | 2022-2025 | |
| Medtronic, INC. | $124.99 | 2021 | |
| Epizyme, INC. | $112.47 | 2021-2022 | |
| Celgene Corporation | $105.49 | 2022-2025 | Reblozyl |
| Seagen INC. | $98.95 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $98.12 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $82.70 | 2021-2023 | Imbruvica |
Show all 50 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zhen Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.